R
Rebecca Rowan
Researcher at Brigham and Women's Hospital
Publications - 4
Citations - 1613
Rebecca Rowan is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Haematopoiesis & Progenitor cell. The author has an hindex of 4, co-authored 4 publications receiving 1555 citations.
Papers
More filters
Journal ArticleDOI
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
Brian J. P. Huntly,Hirokazu Shigematsu,Kenji Deguchi,Benjamin H. Lee,Shinichi Mizuno,Nicky Duclos,Rebecca Rowan,Sonia M Amaral,David P. Curley,Ifor R. Williams,Koichi Akashi,D. Gary Gilliland,D. Gary Gilliland +12 more
TL;DR: It is demonstrated that some, but not all, leukemia oncogenes can confer properties of leukemic stem cells to hematopoietic progenitors destined to undergo apoptotic cell death.
Journal ArticleDOI
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype
Joseph D. Growney,Hirokazu Shigematsu,Zhe Li,Benjamin H. Lee,Jennifer Adelsperger,Rebecca Rowan,David P. Curley,Jeffery L. Kutok,Koichi Akashi,Ifor R. Williams,Nancy A. Speck,D. Gary Gilliland +11 more
TL;DR: It is indicated that Runx1 deficiency has markedly different consequences during development compared with adult hematopoiesis, and insight into the phenotypic manifestations of Runx 1 deficiency in hematoietic malignancies is provided.
Journal ArticleDOI
MOZ-TIF2, but Not BCR-ABL, Confers Properties of Leukemic Stem Cells to Committed Murine Hematopoietic Progenitors.
Brian J. P. Huntly,Hirokazu Shigematzu,Kenji Deguchi,Benjamin H. Lee,Shinichi Mizuno,Nicky Duclos,Rebecca Rowan,Sonia M Amaral,David P. Curley,Ifor R. Williams,Koichi Akashi,Gary Gilliland +11 more
TL;DR: In this article, the authors tested the ability of representative leukemia oncogenes to transform committed myeloid progenitor cells that lack the capacity for self-renewal, and showed that an active MOZ-TIF2, but not BCR-ABL, can collaborate with mutations induced by retroviral mutagenesis to confer properties of leukemic stem cells to committed progenitors.
Journal ArticleDOI
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
Jan Cools,Elizabeth H. Stover,Christina L. Boulton,Christina L. Boulton,Jason Gotlib,Robert D. Legare,Sonia M Amaral,David P. Curley,Nicole Duclos,Rebecca Rowan,Jeffery L. Kutok,Benjamin H. Lee,Ifor R. Williams,Steven Coutre,Richard Stone,Daniel J. DeAngelo,Peter Marynen,Paul W. Manley,Thomas Meyer,Doriano Fabbro,Donna Neuberg,Ellen Weisberg,James D. Griffin,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland +25 more
TL;DR: KPC412 is effective for treatment of FIP1L1-PDGFRalpha-induced disease and of imatinib-induced resistance due to the T674I mutation and the potential of alternative kinase inhibitors to overcome resistance in target tyrosine kinases is demonstrated.